Maze Therapeutics exec sells 6,434 shares

Maze Therapeutics’ CSBO reported selling 6,434 shares to cover tax withholding from RSU vesting, using weighted-average priced market trades.

Available on EDGAR 09/04/2026 - 04:26 PM EDT Accepted by SEC EDGAR 09/04/2026 - 04:25 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Maze Therapeutics, Inc. (MAZE) reports that officer Atul Dandekar, its CSBO, sold 6,434 shares of Common Stock on September 2 and 3, 2026. The company states these sales were made to satisfy tax withholding obligations arising from the vesting of restricted stock units and not as discretionary open-market sales. The shares were sold in multiple transactions at weighted average prices within ranges from $25.743 to $27.40 per share, and no Rule 10b5-1 trading plan is reported.

Insider Trade Summary

Net Seller: 6,434 shares

Net Sell 4 txns

Insider Dandekar Atul

Role CSBO

Sold 6,434 shs ($169K)

Type	Security	Shares	Price	Value
Sale	Common Stock F1, F4	3,207	$26.0133	$83K
Sale	Common Stock F1	36	$25.81	$929.16
Sale	Common Stock F1, F2	2,800	$26.376	$74K
Sale	Common Stock F1, F3	391	$27.1211	$11K

Holdings After Transaction: Common Stock — 32,316 shares (Direct)

Footnotes (4)

1. F1. The reported transaction represents shares of the Issuer's Common Stock sold to satisfy tax withholding obligations incurred in connection with the vesting of restricted stock units.
2. F2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.03 to $27.00 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnotes 3 and 4 of this Form 4.
3. F3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.055 to $27.40 per share, inclusive.
4. F4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.743 to $26.65 per share, inclusive.

Key Figures

Total shares sold: 6,434 shares Shares sold on September 3, 2026 (larger block): 3,207 shares Shares sold on September 3, 2026 (smaller block): 36 shares +4 more

7 metrics

Total shares sold 6,434 shares Common Stock sold by Atul Dandekar on September 2–3, 2026

Shares sold on September 3, 2026 (larger block) 3,207 shares Common Stock at a weighted average price of $26.0133 per share

Shares sold on September 3, 2026 (smaller block) 36 shares Common Stock at $25.81 per share

Shares sold on September 2, 2026 (first block) 2,800 shares Common Stock at a weighted average price of $26.376 per share

Shares sold on September 2, 2026 (second block) 391 shares Common Stock at a weighted average price of $27.1211 per share

Price range for one sale block $26.03–$27.00 per share Underlying trade range for the $26.376 weighted average price block

Overall trade price ranges $25.743–$27.40 per share Ranges across multiple weighted-average sale blocks in the filing

Key Terms

tax withholding obligations, restricted stock units, weighted average price

3 terms

tax withholding obligations financial

"shares of the Issuer's Common Stock sold to satisfy tax withholding obligations"

restricted stock units financial

"obligations incurred in connection with the vesting of restricted stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

weighted average price financial

"The price reported in Column 4 is a weighted average price"

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did MAZE officer Atul Dandekar report in this Form 4?

He reported selling 6,434 shares of Maze Therapeutics Common Stock on September 2 and 3, 2026. The company explains these sales were made to satisfy tax withholding obligations resulting from the vesting of restricted stock units.

Were the MAZE share sales by Atul Dandekar discretionary or for tax withholding?

The filing states the reported transactions represent shares sold to satisfy tax withholding obligations incurred in connection with the vesting of restricted stock units, indicating they were for tax withholding rather than discretionary portfolio sales.

How many MAZE shares did Atul Dandekar sell and on which dates?

According to the Form 4, Atul Dandekar sold a total of 6,434 shares of Common Stock in four transactions on September 2, 2026 and September 3, 2026.

At what prices were the MAZE shares sold in this Form 4?

Per-share prices reported are $26.0133, $25.81, $26.376, and $27.1211, each described as a weighted average price. Footnotes state the underlying trades occurred in ranges from $25.743 to $27.40 per share.

Was a Rule 10b5-1 trading plan used for these MAZE transactions?

No. The document-level Rule 10b5-1 checkbox is not checked, and there is no footnote indicating that the transactions were made pursuant to a Rule 10b5-1 trading plan.

Does the Form 4 disclose any MAZE derivative or option transactions for Atul Dandekar?

No. The reported transactions all involve Common Stock as non-derivative securities, and the derivative transaction summary shows no derivative transactions in this filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Dandekar Atul

(Last) (First) (Middle)

C/O MAZE THERAPEUTICS, INC.

171 OYSTER POINT BOULEVARD, SUITE 300

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Maze Therapeutics, Inc. [ MAZE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CSBO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/02/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/02/2026		S(1)		2,800	D	$26.376(2)	35,950	D
Common Stock	09/02/2026		S(1)		391	D	$27.1211(3)	35,559	D
Common Stock	09/03/2026		S(1)		3,207	D	$26.0133(4)	32,352	D
Common Stock	09/03/2026		S(1)		36	D	$25.81	32,316	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The reported transaction represents shares of the Issuer's Common Stock sold to satisfy tax withholding obligations incurred in connection with the vesting of restricted stock units.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.03 to $27.00 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnotes 3 and 4 of this Form 4.

3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.055 to $27.40 per share, inclusive.

4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.743 to $26.65 per share, inclusive.

	/s/ Courtney Phillips, as attorney-in-fact	09/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)